

ID	Transaction Description	Deal type	Transferor	Transferee	Total value (RMB)	Upfront (RMB)	Upfront %	Total value(USD)	Upfront (USD)	Total M\$	Upfront M\$	Transaction Item	Disease	Clinical Phase	Date
1	Fosun Pharma's Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar	Outbound China	Henlius Biotech	Sandoz			10.30%	301,000,000.00	31,000,000.00	301.00	31.00	Ipilimumab	Cancer	Pipeline Phase I	2025-04-29
2	Shanghai Henlius and Alvogen Korea Ink Licensing Deal for HanSiZhuang (Cepplumab)	Outbound China	Henlius Biotech	Alvogen Korea			4.46%	112,000,000.00	5,000,000.00	112.00	5.00	Stulzumab	Cancer	Market launch	2025-04-27
3	Zhejiang Jolly Pharma Invests in Lingyi Biotech for Gene Therapy Development	Domestic Transactions in China	Lingyi Biotech	Jolly Pharma	20,000,000.00			2,744,915.04		2.74		LY-NB01	Nervous system	Pipeline Phase I	2025-04-27
4	Shanghai Escugen Partners with ConjugateBio on EZW-Fit Platform for ADC Development	Outbound China	Escugen	ConjugateBio								EZW-Fit Platform Technology	Cancer	Molecular discovery	2025-04-25
5	Baheal Partners with Jilintai for Commercialization of Technetium-99m-labeled Imaging Agent	Domestic Transactions in China	Jilintai Pharma	Baheal Pharma	50,000,000.00			6,935,005.13		6.94		Technetium-99m-labeled hydrazinyl/nicotinamide-polyethylene glycol-bicyclic RGD peptide	Cancer	Pipeline Phase II	2025-04-24
6	QYuns Therapeutics Signs Global Licensing Deal with Caldera for Autoimmune BtAb	Outbound China	QYuns Therapeutics	Caldera				555,000,000.00		555.00		QX030N	Autoimmunity	Preclinical	2025-04-24
7	JW Therapeutics Enters Licensing Pact with Juno Therapeutics for siLVV Process	Outbound China	JW Therapeutics	BMS				10,000,000.00		10.00		JW siLVV production process and related technical knowledge	Cancer	Molecular discovery	2025-04-18
8	Velavigo and Olin Biosciences Ink licensing Deal for First-in-Class BtAb VBS-102	Outbound China	Velavigo	Olin Biosciences				440,000,000.00		440.00		VBS-102	Ophthalmology	Precinical	2025-04-18
9	Sanofi Licenses First-in-Class BtAbs from Erendil Labs for Autoimmune and BD Treatment	Outbound China	Helixon Therapeutics	Sanofi			6.78%	1,845,000,000.00	125,000,000.00	1,845.00	125.00	HXXN-1002 , HXXN-1003	Autoimmunity	Precinical	2025-04-17
10	Zhaocke Ophthalmology Signs Distribution Agreements with Thailand's Interpharma for Myopia and Presbyopia Treatments	Outbound China	Zhaocke Ophthalmology	Interpharma								NVK002, BRIMOCHOL PF and six generic glaucoma medications	Ophthalmology	Pipeline Phase II, Market launch	2025-04-16
11	Zhaocke Ophthalmology Launches Phase II Study for Brimochol PF in Presbyopia Treatment	Outbound China	Zhaocke Ophthalmology	Lunatus								BRIMOCHOL PF	Ophthalmology	Pipeline Phase II	2025-04-14
12	HuidaGene's hCas12Max Licensed to Vita Therapeutics for Neuromuscular Cell Therapy	Outbound China	HuidaGene Therapeutics	Vita Therapeutics								hCas12Max nuclease and its optimized gRNA	Nervous system	Precinical	2025-04-09
13	Hengrui Pharmaceuticals Licenses SH7280 to Merck for Assisted reproduction	Outbound China	Hengrui Pharma	Merck KGaA				17,094,444.00	17,094,444.00	17.09	17.09	SH7280	Urogenital	Pipeline Phase II	2025-04-07
14	Abbisio Therapeutics Secures \$85M from Merck for Pimicotinib Global Rights	Outbound China	Abbisio Therapeutics	Merck KGaA				85,000,000.00		85.00		Pimicotinib	Cancer	Pipeline Phase II	2025-04-01
15	Organon Acquires U.S. Rights to TORIDENCE from Biogen	Outbound China	Bio-Thera Solutions	Organon								Tocilizumab biosimilars	Autoimmunity	Market launch	2025-04-01

For more insights, follow [Fineline Info & Tech](#).

<https://fbcube.com>